Neurological irAEs are infrequently discussed because they are rare, affecting <1% of patients [4,5], and more common in patients receiving anti-PD-1/PD-L1 inhibitors (6%) compared to those on anti-cytotoxic T-lymphocyte-associated protein-4 (CTLA-4) treatment (4%) [6]. In recent studies, the widely used immunotherapy has been associated with rapid-onset myopathies such as myasthenia gravis [6] and chronic inflammatory demyelinating polyradiculoneuropathy syndromes [7]. This evidence concerns the gene CTLA4 and myasthenia gravis.